Herpes zoster (HZ) is a neurocutaneous disease that causes significant morbidity
worldwide. The disease is caused by the reactivation of the varicella-zoster virus (VZV) …

This report provides recommendations for budget holders and decision makers in high-,
middle, and low-income countries requiring economic analyses of new vaccination …

Recommendations of the Advisory Committee on Immunization Practices for use of herpes
zoster vaccines - ScienceDirect Skip to main contentSkip to article Elsevier logo Journals & …

There is emerging evidence that the live herpes zoster (shingles) vaccine might protect
against dementia. However, the existing data are limited and refer only to the live vaccine …

Background: Approximately 1 million new cases of herpes zoster (HZ) occur in the United
States annually, including 10%–20% with herpes zoster ophthalmicus (HZO). Postherpetic …

Abstract In the United States, herpes zoster (HZ) and related complications are estimated to
result in approximately $1.3 billion in medical care costs and $1.7 billion in indirect costs …

Background: The US Advisory Committee on Immunization Practices recently developed
recommendations for use of a new recombinant zoster vaccine (RZV). Objective: To …

The objective of this study was to critically review the cost-effectiveness (CE) of the
recombinant zoster vaccine (RZV) against herpes zoster (HZ). A literature review was …

Background: Currently, the recombinant subunit vaccine and live attenuated vaccine in the
prevention of herpes zoster are approved for marketing in China. This study aims to evaluate …

Shingrix (Recombinant zoster vaccine, RZV) was approved in October 2017 in the United
States (US) for the prevention of herpes zoster in adults aged 50 years and older. The …